Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
55 Results for "
Menin-MLL
" in MedChemExpress (MCE) Product Catalog:
Products (55)
55 Results for "Menin-MLL" in MCE Product Catalog:
Cat. No.: HY-117948
CAS No.: 1560968-49-1
Research Areas:
ML399 is a Menin-MLL1 protein-protein interaction inhibitor with an IC50 of 90 nM. ML399 inhibits the proliferation of transformed mouse bone marrow cells. ML399 binds to the hERG potassium channel, exhibits superior in vitro physicochemical, drug metabolism and pharmacokinetic (DMPK) parameters, and has an extended half-life in rodents. ML399 can be used for research on acute myeloid leukemia and acute lymphoblastic leukemia .
Research Areas:
MI-389 is a potent menin-MLL interaction inhibitor (IC50=25 nM) and a CRBN-recruiting, GSPT1-targeted PROTAC degrader. MI-389 upregulates myeloid differentiation-related genes that are lowly expressed in primitive hematopoietic progenitor cells, thereby inducing myeloid differentiation phenotypic changes in MLL-rearranged leukemia cells. MI-389 competitively blocks the MG-H1-RAGE interaction to interfere with the AGEs-RAGE pathway, thus alleviating AGEs-induced HUVEC injury . MI-389 can be used in studies related to MLL-rearranged acute leukemia .
Cat. No.: HY-133738
CAS No.: 2377335-74-3
Target:
Research Areas:
M-808 is a highly potent and efficacious covalent Menin-MLL interaction inhibitor, with a binding IC50 value of 2.6 nM .
Cat. No.: HY-157814
Target:
Research Areas:
Menin-MLL inhibitor-25 (compound A6) is a potent Menin-MLL interaction inhibitor with an IC50 value of 0.38 µM. Menin-MLL inhibitor-25 shows anti-proliferative activity. Menin-MLL inhibitor-25 induces apoptosis and cell cycle arrest at G0/G1 phase. Menin-MLL inhibitor-25 reverses the differentiation arrest .
Cat. No.: HY-163798
Target:
Research Areas:
Menin-MLL inhibitor 33 (compound 15-a) is a potent Menin-MLL inhibitor with an IC50 value of 3.6 nM. Menin-MLL inhibitor 33 shows antiproliferative activity .
Cat. No.: HY-15222A
Target:
Research Areas:
Menin-MLL inhibitor MI-2 dihydrochloride is a competitive and selective Menin-MLL interaction inhibitor with an IC50 value of 446 nM and a Ki value of 158 nM. Menin-MLL inhibitor MI-2 dihydrochloride downregulates the expression of target genes such as HOXA9 and MEIS1, inhibits proliferation of leukemia cells and induces apoptosis and differentiation. Menin-MLL inhibitor MI-2 dihydrochloride is proming for rasearch of MLL-rearranged acute leukemias (e.g., AML, ALL) .
Cat. No.: HY-156130
Target:
Research Areas:
Menin-MLL inhibitor 29 (Compound C1) is a Menin-MLL PPI inhibitor. Menin-MLL inhibitor 29 binds to Menin with a KD value of 138 nM, and inhibits the binding of Menin to MBM1 (Menin-binding motif 1) with an IC50 value of 46 nM. Menin-MLL inhibitor 29 inhibits HepG2 and Hep3B hepatoma cell proliferation (IC50s: 0.31 μM and 0.71 μM). Menin-MLL inhibitor 29 inhibits tumor growth .
Cat. No.: HY-129167
CAS No.: 2169916-13-4
Target:
Research Areas:
Menin-MLL inhibitor 4 is an inhibitor of Menin- MLL (mixed-lineage leukemia protein) interaction extracted from patent WO2017214367, compound example 1. Menin-MLL inhibitor 4 has antitumor activity .
Cat. No.: HY-168182
CAS No.: 3096376-30-3
Target:
Research Areas:
Menin-MLL inhibitor 34 (Compound 37) is a selective and potent Menin-MLL inhibitor, with an IC50 of 18.21 nM for Menin. Menin-MLL inhibitor 34 has long-lasting anti-leukemic effects by reducing Menin protein levels and down-regulating MEN1 transcription .
Target:
Research Areas:
Menin-MLL inhibitor 19, a potent exo-aza spiro inhibitor of menin-mll interaction, example A17, extracted from patent WO2019120209A1. Menin-MLL inhibitor 19 can be used for the reseaech of various diseases, such as cancer, myelodysplastic syndrome (MDS) and diabetes .
Cat. No.: HY-P10066
CAS No.: 2863656-86-2
Target:
Research Areas:
Cat. No.: HY-114162R
CAS No.: 2169916-18-9
Synonyms: SNDX-50469 (Standard)
Research Areas:
VTP50469 (Standard) is the analytical standard of VTP50469. This product is intended for research and analytical applications. VTP50469 is a potent, highly selective and orally active Menin-MLL interaction inhibitor with a Ki of 104 pM. VTP50469 has potently anti-leukemia activity .
Cat. No.: HY-124069
CAS No.: 2173582-08-4
Target:
Research Areas:
M-525 is a first-in-class, highly potent, irreversible and covalent menin-MLL protein-protein interaction inhibitor. M-525 binds to menin with an IC50 of 3 nM and achieves low nanomolar potencies in cell growth inhibition and in suppression of MLL regulated gene expression in MLL leukemia cells. Anti-leukemia activity .
Cat. No.: HY-148367A
Target:
Research Areas:
(1s,4s)-Menin-MLL inhibitor-23 is the enantiomer of Menin-MLL inhibitor-23 (HY-148367). Menin-MLL inhibitor-23 (Example 99A) is a menin-MLL interaction inhibitor .
Cat. No.: HY-148669B
Purity: 98.37%
Synonyms: (S)-JNJ-75276617 oxalate; (S)-Menin-MLL inhibitor 24 oxalate
Target:
Research Areas:
(S)-Bleximenib (oxalate) is a S-Enantiomer of Bleximenib oxalate (HY-148669A). Bleximenib (JNJ-75276617) oxalate is an orally active and selective menin-KMT2A inhibitor, with IC50 values of 0.1 nM, 0.045 nM, and ≤0.066 nM for humans, mice, and dogs, respectively. Bleximenib oxalate can inhibit the proliferation and induce apoptosis and differentiation of tumor cells. Bleximenib oxalate can be used in the research of tumors such as leukemia .
Cat. No.: HY-160018
CAS No.: 2163769-52-4
Target:
Research Areas:
BAY-155 is a potent and selective menin-MLL tool inhibitor, with an IC50 of 8 nM. BAY-155 leads to a strong expression down-regulation of the MEIS1 gene and up-regulation of CD11b and MNDA genes. BAY-155 shows anti-proliferative effects in AML/ALL (acute myeloid/lymphoblastic leukemia) models .
Cat. No.: HY-176732
Target:
Research Areas:
MJ-26 is an inhibitor targeting Menin. MJ-26 has high binding affinity (Ki: 0.56 μM) and significant antiproliferative activity. MJ-26 works by inhibiting Menin-MLL interaction and inducing Menin protein degradation. MJ-26 has significant antitumor effects on acute myeloid leukemia (AML). MJ-26 can be used in AML research .
Cat. No.: HY-155797
CAS No.: 2654081-27-1
Synonyms: (S)-JNJ-75276617; (S)-Menin-MLL inhibitor 24
Target:
Research Areas:
(S)-Bleximenib (Compound 28) ((S)-JNJ-75276617) is an isoform of Bleximenib (HY-148669). (S)-Bleximenib shows an IC50 greater than 1 μM in the MEIS1 mRNA expression assay. (S)-Bleximenib can be used in the research of acute myeloid leukemia .
Cat. No.: HY-186043
CAS No.: 2654080-48-3
Target:
Research Areas:
Menin-MLL-IN-35 (compound 286) is an inhibitor of menin/MLL protein/protein interaction with an IC50 value of 0.096 μM in MEIS1 mRNA expression. Menin-MLL-IN-35 can be used in the research of cancer, myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), and diabetes .
Cat. No.: HY-186044
CAS No.: 2654078-52-9
Target:
Research Areas:
Menin-MLL-IN-36 (compound 398) is an inhibitor of menin/MLL protein/protein interaction with an IC50 value of 0.043 μM in MEIS1 mRNA expression. Menin-MLL-IN-36 can be used in the research of cancer, myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), and diabetes .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
